LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Hutchison China MediTech Ltd ADR

Cerrado

SectorSalud

14.93 -2.03

Resumen

Variación precio

24h

Actual

Mínimo

14.65

Máximo

15.17

Métricas clave

By Trading Economics

Ingresos

-6.9M

6M

Ventas

9.4M

162M

P/B

Media del Sector

74.2

50.291

Margen de beneficio

3.676

Empleados

1,811

EBITDA

5.6M

-5M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+35.92% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-153M

2.5B

Apertura anterior

16.96

Cierre anterior

14.93

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

27 jun 2025, 20:51 UTC

Ganancias

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 jun 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 jun 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

27 jun 2025, 20:48 UTC

Charlas de Mercado

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 jun 2025, 20:46 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

27 jun 2025, 20:46 UTC

Charlas de Mercado

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 jun 2025, 19:31 UTC

Charlas de Mercado

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 jun 2025, 19:19 UTC

Charlas de Mercado

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 jun 2025, 19:16 UTC

Charlas de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 jun 2025, 18:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 jun 2025, 18:42 UTC

Charlas de Mercado

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 jun 2025, 18:39 UTC

Charlas de Mercado
Ganancias

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 jun 2025, 18:29 UTC

Charlas de Mercado

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 jun 2025, 18:18 UTC

Charlas de Mercado

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 jun 2025, 18:16 UTC

Charlas de Mercado

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 jun 2025, 17:16 UTC

Charlas de Mercado

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 jun 2025, 17:08 UTC

Ganancias

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 jun 2025, 16:52 UTC

Adquisiciones, fusiones, absorciones

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 jun 2025, 16:22 UTC

Ganancias

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 jun 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

27 jun 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 jun 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

27 jun 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

27 jun 2025, 15:59 UTC

Charlas de Mercado

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 jun 2025, 15:56 UTC

Charlas de Mercado

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR Esperado

Precio Objetivo

By TipRanks

35.92% repunte

Estimación a 12 meses

Media 20.85 USD  35.92%

Máximo 27 USD

Mínimo 14.7 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

1

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.24 / 14.78Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.